Zoe Li
About Zoe Li
Zoe Li is the Associate Director at Bristol-Myers Squibb in Shanghai, China, with over a decade of experience in the pharmaceutical industry, focusing on oncology and clinical trials.
Title and Role at Bristol-Myers Squibb
Zoe Li serves as an Associate Director at Bristol-Myers Squibb, located in Shanghai City, China. She has been with the company since 2012. In her role, she leads the China full development team for early assets and acts as the central medical monitor for Phase 3 China registration trials. Additionally, she is the leading physician for NDA projects within China.
Previous Experience at Shanghai Roche Pharmaceutical Ltd.
Before joining Bristol-Myers Squibb, Zoe Li was an Associate Medical Manager at Shanghai Roche Pharmaceutical Ltd. from 2010 to 2012. During her tenure in Shanghai, she gained valuable experience that helped pave the way for her current role in the pharmaceutical industry.
Medical Career at Shanghai 1st Hospital
Zoe Li's career began at Shanghai 1st Hospital, where she served as an attending doctor in the Oncology department from 2001 to 2010. Throughout her nine-year stint, she focused on oncology, gaining substantial clinical experience that would later inform her work in pharmaceutical development and clinical trials.
Educational Background in Medicine
Zoe Li holds a Master's degree in Medicine with a focus on Gastric Cancer from Shanghai Jiaotong University's School of Medicine, where she studied from 2005 to 2008. Additionally, she earned a Bachelor's degree in Clinical Medicine from the Shanghai Medical College of Fudan University, graduating in 2001. Her comprehensive education has provided her with a robust foundation in medical science and clinical practice.
Experience in Oncology and Clinical Trials
With over a decade of experience in the pharmaceutical industry, Zoe Li has specialized in oncology and clinical trials. Her work includes significant contributions to the China registration trials for new drugs and playing a crucial role in the trial process. Her extensive background in both clinical and pharmaceutical settings makes her a key asset in drug development and medical monitoring.